DAFNA Capital Management’s Cidara Therapeutics CDTX Stock Holding History

DAFNA Capital Management’s Portfolio CDTX Stock Details CDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-5,000	Closed	-$199K	–	84
2019 Q3	$199K	Sell	5,000 -5,638	-53%	-$190K	0.07%	83
2019 Q2	$357K	Hold	10,638	–	–	0.13%	76
2019 Q1	$564K	Hold	10,638	–	–	0.24%	63
2018 Q4	$500K	Hold	10,638	–	–	0.25%	58
2018 Q3	$936K	Hold	10,638	–	–	0.38%	53
2018 Q2	$1.11M	Buy	10,638 +9,481	+819%	+$895K	0.52%	48
2018 Q1	$93K	Sell	1,157 -9,663	-89%	-$1.32M	0.05%	71
2017 Q4	$1.47M	Buy	10,820 +397	+4%	+$60.2K	0.79%	39
2017 Q3	$1.69M	Hold	10,423	–	–	1.05%	29
2017 Q2	$1.56M	Hold	10,423	–	–	1.12%	32
2017 Q1	$1.63M	Buy	10,423 +2,427	+30%	+$426K	1.38%	26
2016 Q4	$1.66M	Buy	+7,996	New	+$1.66M	1.46%	27

Other funds holding CDTX

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return

IVM

InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACM

Alethea Capital Management Mercer Island, Washington $241M AUM 112.74% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.81B AUM 83.9% 1-Year Est. Return

DAFNA Capital Management's CDTX Position: Q4 2019 in Review

DAFNA Capital Management sold out of Cidara Therapeutics (CDTX) in Q4 2019, closing a stake of 5,000 shares — an estimated $199K sold.

DAFNA Capital Management first reported a position in CDTX in Q4 2016 and held it in 12 quarters. The position peaked at $1.69M in Q3 2017. 50 funds tracked by Wall St. Rank hold CDTX as of Q4 2019.

DAFNA Capital Management reported no remaining Cidara Therapeutics position as of Q4 2019 after selling out during the quarter.
DAFNA Capital Management sold 5,000 Cidara Therapeutics shares in Q4 2019, an estimated $199K.
DAFNA Capital Management first reported a position in Cidara Therapeutics in Q4 2016 and held it in 12 quarters.
DAFNA Capital Management's Cidara Therapeutics position peaked at $1.69M in Q3 2017.
50 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q4 2019.

Based on DAFNA Capital Management's 13F filing for Q4 2019, filed 14 Feb 2020.